Unlock stock picks and a broker-level newsfeed that powers Wall Street.

DSM-Firmenich's (AMS:DSFIR) Earnings Are Weaker Than They Seem

In This Article:

DSM-Firmenich AG's (AMS:DSFIR) stock was strong after they recently reported robust earnings. We did some analysis and think that investors are missing some details hidden beneath the profit numbers.

View our latest analysis for DSM-Firmenich

earnings-and-revenue-history
ENXTAM:DSFIR Earnings and Revenue History March 8th 2025

How Do Unusual Items Influence Profit?

Importantly, our data indicates that DSM-Firmenich's profit received a boost of €55m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. If DSM-Firmenich doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On DSM-Firmenich's Profit Performance

Arguably, DSM-Firmenich's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that DSM-Firmenich's statutory profits are better than its underlying earnings power. The good news is that it earned a profit in the last twelve months, despite its previous loss. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. In terms of investment risks, we've identified 1 warning sign with DSM-Firmenich, and understanding this should be part of your investment process.

This note has only looked at a single factor that sheds light on the nature of DSM-Firmenich's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.